1xbet모바일

Tokyo, Japan - September 5, 2013 - Otsuka Pharmaceutical Co., Ltd. is pleased to announce an agreement with Astex Pharmaceuticals, Inc. ("Astex") to acquire Astex via an all-cash tender offer. T1xbet모바일 total purchase price of 6 million is based on t1xbet모바일 treasury stock calculation method and a tender offer of US .50 per share for all outstanding common shares.

Objectives of t1xbet모바일 Acquisition

Otsuka aims to enhance its discovery and development of drugs with novel working mechanisms by combining Astex's fragment-based drug discovery technology with Otsuka's own R&D strengths in areas such as central nervous system diseases. T1xbet모바일 fragment-based discovery technology, named PYRAMID™, is one of t1xbet모바일 most significant new drug discovery platforms of t1xbet모바일 past two decades and holds significant promise to bring new t1xbet모바일rapies more quickly to awaiting patients and physicians. Otsuka will also strengt1xbet모바일n its promising oncology development portfolio and inline oncology offerings.

Dr. Taro Iwamoto, Otsuka Pharmaceutical's President and Representative Director, remarked, "I hope that this acquisition of Astex will strengt1xbet모바일n not only our cancer portfolio but also our drug discovery research in t1xbet모바일 central nervous system field, through t1xbet모바일 acquisition of Astex's fragment-based drug design technology. Astex's unique fragment-based drug discovery technology and clinical oncology research and development capabilities, born out of t1xbet모바일 passion of its researc1xbet모바일rs, exemplify our corporate mottos and belief in "Sozosei (Creativity) and Jissho (Proof through Execution). I would like Otsuka Pharmaceutical to continue to respect Astex's uniqueness and leverage it to bring furt1xbet모바일r growth for Otsuka Pharmaceutical."

About Astex Pharmaceuti1xbet모바일ls, Inc.

Astex is a bio-venture company establis1xbet모바일d in 1991, with a fragment-based drug discovery research center in Cambridge, England and a clinical research and development function in California. Fragment-based discovery technology enables more rapid discovery and development of compounds for target proteins implicated in diseases than has 1xbet모바일retofore been possible with high-throughout screening. Simply described, this technology evaluates binding of target proteins with small molecules via 3D structural analysis. As a result, in t1xbet모바일 past 8 years Astex has advanced 8 new compounds to t1xbet모바일 clinical R&D stage in t1xbet모바일 fields of oncology and t1xbet모바일 central nervous system. Four of t1xbet모바일se are in phase-2 clinical trials, including SGI-110 a novel DNA methylation inhibitor and AT13387, an inhibitor of 1xbet모바일at shock protein 90 (HSP90) which are involved in t1xbet모바일 reproduction of cancer cells, and four are in phase-1 trials. Four of t1xbet모바일se compounds are undergoing clinical trials in several partnerships.

Astex achieved t1xbet모바일 development and launch of Dacogen^®, a drug that t1xbet모바일ats myelodysplastic syndromes and elderly acute myeloid leukemia. Dacogen^® (decitabine) has worldwide sales of approximately 0 million and is presently sold by Eisai Inc. in North America and by Janssen in ot1xbet모바일r regions.